Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 5—May 2019
Dispatch

Value of PCR, Serology, and Blood Smears for Human Granulocytic Anaplasmosis Diagnosis, France

Yves HansmannComments to Author , Benoit Jaulhac, Pierre Kieffer, Martin Martinot, Elisabeth Wurtz, Régis Dukic, Geneviève Boess, André Michel, Christophe Strady, Jean François Sagez, Nicolas Lefebvre, Emilie Talagrand-Reboul, Xavier Argemi, and Sylvie De Martino
Author affiliations: Université de Strasbourg, Strasbourg, France (Y. Hansmann, B. Jaulhac, E. Talagrand-Reboul, S. De Martino); Hôpitaux Universitaires de Strasbourg, Strasbourg (Y. Hansmann, N. Lefebvre, X. Argemi); Centre National de Référence des Borrelia, Strasbourg (B. Jaulhac, S. De Martino); Centre Hospitalier Emile Muller, Mulhouse, France (P. Kieffer); Centre Hospitalier Pasteur, Colmar, France (M. Martinot); Centre Hospitalier Saverne, Saverne, France (E. Wurtz); Centre Hospitalier de Haguenau, Haguenau, France (R. Dukic); Centre Hospitalier de Guebwiller, Guebwiller, France (G. Boess); Centre Hospitalier de Wissembourg, Wissembourg, France (A. Michel); Polyclinique Saint André, Reims, France (C. Strady); Centre Hospitalier Sélestat, Sélestat, France (J.F. Sagez)

Cite This Article

Abstract

We prospectively examined the effectiveness of diagnostic tests for anaplasmosis using patients with suspected diagnoses in France. PCR (sensitivity 0.74, specificity 1) was the best-suited test. Serology had a lower specificity but higher sensitivity when testing acute and convalescent samples. PCR and serology should be used in combination for anaplasmosis diagnosis.

Human granulocytic anaplasmosis (HGA) is a tickborne intracellular bacterial infection caused by Anaplasma phagocytophilum. The disease is present in North America, Europe, and northern Asia, areas with Ixodes ricinus ticks, the primary vector for transmission to humans (1,2). Clinical manifestations of disease include acute fever, headache, and myalgia occurring 2–3 weeks after tick bite. Diagnosis requires the isolation of A. phagocytophilum in blood culture, the presence of morulae in polymorphonuclear cells after May Grünwald-Giemsa staining of peripheral blood smears, positive serologic results (seroconversion or high titer of specific antibodies), or a positive A. phagocytophilum PCR result. The May Grünwald-Giemsa stain test has a low sensitivity (3); PCR and serology are more widely available, but their diagnostic value is not well established. The aim of our study was to compare the diagnostic values of the available microbiological tests in a prospectively selected series of patients with clinical signs and symptoms consistent with an HGA diagnosis.

The Study

In this prospective, multicenter study, we enrolled symptomatic patients living in Alsace, a region of northeastern France where tickborne diseases are highly endemic. Patients gave written, informed consent to participate in our study, which was approved by the ethics committee of the University Hospital of Strasbourg (Strasbourg, France).

We included patients if they had 1 of the following combinations of signs and symptoms occurring no more than 4 weeks after a tick bite: 1) fever or other symptom presumed related to a tick bite, 2) fever plus thrombocytopenia with or without leukopenia or elevated liver enzyme levels, 3) thrombocytopenia with or without leukopenia, or 4) elevated liver enzyme levels without fever. The first visit included clinical and epidemiologic evaluations and the collection of blood samples for A. phagocytophilum serology, May Grünwald-Giemsa staining, and A. phagocytophilum–specific PCR. We did not culture for A. phagocytophilum. An etiologic investigation was also conducted to obtain a differential diagnosis. After >4 weeks, a second visit was scheduled to obtain a clinical evaluation, A. phagocytophilum serology, and (if necessary) a complete differential diagnosis.

We stratified patients into 3 groups on the basis of their diagnosis. One group included controls, who were patients with a clinical and microbiologically confirmed nonanaplasmosis diagnosis. The second group included anaplasmosis patients defined by >1 of the following criteria: intraleukocyte morulae on blood smears, a positive PCR result for Anaplasma, a 4-fold increased antibody titer for A. phagocytophilum in the follow-up sample or a seroconversion (i.e., change in antibody titer from negative in first sample to >1:64 in second sample), or a high antibody titer for Anaplasma (>1:256) by indirect immunofluorescence antibody assay. The third group were patients without any diagnosis.

We performed DNA extraction, PCR, and serologic testing blinded to sample identification as previously described (4). The PCR targeted the A. phagocytophilum msp2/p44 gene. We performed serologic testing using the Anaplasma phagocytophilum IFA IgG assay (Focus Diagnostics, http://www.focusdx.com) (4). Trained staff examined May Grünwald-Giemsa–stained smear preparations of whole blood samples for intracellular morulae. We collected data by using EpiData version 3.1.2701.2008 (http://epidata.dk) and extracted data to Excel spreadsheets (Microsoft, https://www.microsoft.com) for analysis. After patient stratification, we estimated the sensitivity and specificity of the different diagnostic tests.

Figure

Thumbnail of Distribution of positive diagnostic test results for patients with confirmed human granulocytic anaplasmosis, France, May 2010–July 2012.

Figure. Distribution of positive diagnostic test results for patients with confirmed human granulocytic anaplasmosis, France, May 2010–July 2012.

During May 2010–July 2012, we enrolled 155 patients into the study, 25 of whom did not complete the second visit. None of these 25 patients had a positive PCR result or an antibody titer >1:256 at the first visit. The remaining 130 patients completed both study visits and were thus included in the study evaluation. Of these 130 patients, 19 had confirmed anaplasmosis diagnoses and 36 were controls with confirmed nonanaplasmosis diagnoses (infections with Borrelia burgdorferi, Epstein-Barr virus, cytomegalovirus, HIV, tick-borne encephalitis virus, Leptospira spp., Babesia spp., parvovirus B19, hantavirus, Francisella tularensis, Plasmodium spp., and Aeromonas spp.). Of the patients with HGA, 84.2% (16/19) met the serologic criteria and 73.7% (14/19) met the PCR criteria (Table; Figure). Fever, the most frequent symptom (89%), was associated with joint and muscle pain. Cytopenia of platelets, neutrophils, or both (74%) and elevated liver enzyme levels (63%) were frequently present.

Calculations of the diagnostic value of each test method showed that PCR had a sensitivity of 0.74 and a specificity of 1 and blood smear staining had a sensitivity of 0.21 and a specificity of 1. Seroconversion or a 4-fold increase of antibody titer had a sensitivity of 0.32 and specificity of 0.97, an antibody titer >1:256 had a sensitivity of 0.58 and specificity of 0.97, and overall serology had a sensitivity of 0.84 and specificity of 0.97.

The interval between the first and second serologic tests for most patients in the anaplasmosis group was 4–8 weeks (mean 49.8 days). Five patients had the second test >8 weeks after the first. Of these patients, 2 seroconverted, 1 experienced a substantial decrease in antibody titer, 1 experienced a substantial increase at week 12, and 1 had a stable antibody titer.

Our study confirms PCR as the gold standard for diagnosis of HGA; this test enabled rapid diagnosis during the acute stage of infection with good sensitivity and excellent specificity. However, the absence of a gold standard diagnostic test to compare our results with is a limitation to our study. A. phagocytophilum culture is the reference test for HGA diagnosis (5,6) but is not well suited for routine use because culturing is time-consuming and not widely performed. The diagnosis of anaplasmosis often involves assessing for the presence of morulae, but this test has low sensitivity (3). In our study, this test was of limited value for HGA diagnosis because whenever morulae were detected on blood smears >1 of the other diagnostic tests were positive. However, May Grünwald-Giemsa staining is the quickest test to do, and when performed by trained staff, positive results are helpful for physicians.

In clinical practice, diagnosis of HGA often relies on serology (79), but 2 limitations are associated with this method: a risk for false-negative results during the acute stage of infection because A. phagocytophilum antibodies are detected on average 11.5 days after symptom onset and a risk for false-positive results because Anaplasma antibodies are detectable in 86.4% of patients for 6–10 months and in 40% of patients up to 2 years after the initial infection (10). Positive serologic criteria are seroconversion, a 4-fold increase in antibody titer, or a stable and high antibody titer (11,12). In our study, we observed that each of these criteria can lead to misdiagnosis at the beginning of infection, as previously reported (13).

PCR is considered the most effective diagnostic method during early stage A. phagocytophilum infection (14,15). Our results confirm this belief, despite our limitation of a small study population. However, if PCR is use alone, HGA might be underdiagnosed.

Conclusions

The presentation of fever in a patient with a history of tick bite does not qualify for an anaplasmosis diagnosis; microbiological tests need to be performed. For anaplasmosis, PCR testing appears to be the most effective diagnostic tool. However, the sensitivity of PCR is <100%, and combining PCR with serologic testing at the first visit appears to be the best strategy for early diagnosis of acute anaplasmosis. In cases of high suspicion for HGA in patients without any diagnosis at the first visit, a second serologic test >4 weeks later can be helpful. A multiplex approach could also be used in such cases to look for differential diagnoses.

Dr. Hansmann is head of the Infectious Disease Department at Strasbourg University Hospital, Strasbourg, France; a member of the Borreliosis group of the European Society of Clinical Microbiology and Infectious Diseases; and involved in designing the tickborne disease national diagnosis and health plan for France. His research interests are tickborne diseases and diagnosis.

Top

Acknowledgment

This study was supported by the French Hospital Clinical Research Program (PHRC HUS 2007–3960).

Top

References

  1. Strle  F. Human granulocytic ehrlichiosis in Europe. Int J Med Microbiol. 2004;293(Suppl 37):2735.PubMed
  2. Dedkov  VG, Simonova  EG, Beshlebova  OV, Safonova  MV, Stukolova  OA, Verigina  EV, et al. The burden of tick-borne diseases in the Altai region of Russia. Ticks Tick Borne Dis. 2017;8:78794. DOIPubMed
  3. Bakken  JS, Dumler  JS. Human granulocytic anaplasmosis. Infect Dis Clin North Am. 2015;29:34155. DOIPubMed
  4. Koebel  C, Kern  A, Edouard  S, Hoang  AT, Celestin  N, Hansmann  Y, et al. Human granulocytic anaplasmosis in eastern France: clinical presentation and laboratory diagnosis. Diagn Microbiol Infect Dis. 2012;72:2148. DOIPubMed
  5. Goodman  JL, Nelson  C, Vitale  B, Madigan  JE, Dumler  JS, Kurtti  TJ, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl J Med. 1996;334:20915. DOIPubMed
  6. Wormser  GP, Aguero-Rosenfeld  ME, Cox  ME, Nowakowski  J, Nadelman  RB, Holmgren  D, et al. Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early lyme disease. J Clin Microbiol. 2013;51:9548. DOIPubMed
  7. Yeh  MT, Mather  TN, Coughlin  RT, Gingrich-Baker  C, Sumner  JW, Massung  RF. Serologic and molecular detection of granulocytic ehrlichiosis in Rhode Island. J Clin Microbiol. 1997;35:9447.PubMed
  8. Kocianová  E, Kost’anová  Z, Stefanidesová  K, Spitalská  E, Boldiš  V, Hucková  D, et al. Serologic evidence of Anaplasma phagocytophilum infections in patients with a history of tick bite in central Slovakia. Wien Klin Wochenschr. 2008;120:42731. DOIPubMed
  9. Aguero-Rosenfeld  ME, Kalantarpour  F, Baluch  M, Horowitz  HW, McKenna  DF, Raffalli  JT, et al. Serology of culture-confirmed cases of human granulocytic ehrlichiosis. J Clin Microbiol. 2000;38:6358.PubMed
  10. Lotric-Furlan  S, Avsic-Zupanc  T, Petrovec  M, Nicholson  WL, Sumner  JW, Childs  JE, et al. Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia. Clin Diagn Lab Immunol. 2001;8:899903.PubMed
  11. Bakken  JS, Haller  I, Riddell  D, Walls  JJ, Dumler  JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis. 2002;34:227. DOIPubMed
  12. Brouqui  P, Bacellar  F, Baranton  G, Birtles  RJ, Bjoërsdorff  A, Blanco  JR, et al.; ESCMID Study Group on Coxiella, Anaplasma, Rickettsia and Bartonella; European Network for Surveillance of Tick-Borne Diseases. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect. 2004;10:110832. DOIPubMed
  13. Lotrič-Furlan  S, Rojko  T, Jelovšek  M, Petrovec  M, Avšič-Županc  T, Lusa  L, et al. Comparison of clinical and laboratory characteristics of patients fulfilling criteria for proven and probable human granulocytic anaplasmosis. Microbes Infect. 2015;17:82933. DOIPubMed
  14. Dumler  JS, Madigan  JE, Pusterla  N, Bakken  JS. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2007;45(Suppl 1):S4551. DOIPubMed
  15. Weil  AA, Baron  EL, Brown  CM, Drapkin  MS. Clinical findings and diagnosis in human granulocytic anaplasmosis: a case series from Massachusetts. Mayo Clin Proc. 2012;87:2339. DOIPubMed

Top

Figure
Table

Top

Cite This Article

DOI: 10.3201/eid2505.171751

Original Publication Date: 3/26/2019

Table of Contents – Volume 25, Number 5—May 2019

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Yves Hansmann, Hôpitaux Universitaires de Strasbourg, Médecine Interne et Maladies Infectieuses et Tropicales 1, Place de l'Hôpital, Strasbourg 67091, France

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: April 17, 2019
Page updated: April 17, 2019
Page reviewed: April 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external